With mHealth apps forecast to generate $189 billion annual revenue to app providers by 2020, pharma companies hoping to jump on the mHealth bandwagon may soon find themselves facing an interesting question — how do I make money from the app?
An antigen is any structure that can be recognized by an antibody, however the binding of the antigen to an antigen receptor (membrane bound antibody) does not necessarily lead to the lymphocyte activation and the development of an immune response. A substance that has the ability to drive an immune response is referred to as an immunogen. An immunogen is also an antigen, but not all antigens are immunogens.
Rheumatoid arthritis (RA) is a chronic inflammatory disease which can lead to the risk of premature death. Traditional guidelines for diagnosing RA were developed in 1987 were dependent on a combination of clinical, laboratory and radiographic features. An update to these guidelines gives assay developers the opportunity to bring test into the point of care setting providing the opportunity for earlier detection and better patient outcomes.
Areas, where lots of people congregate, offer the perfect breeding ground for norovirus. The quarantine of approx. 1,200 staff, days before the start of the 2018 Pyeongchang Winter Olympic Games was just one high-profile case reported in 2018 (1).
The immune system has the capacity to develop antibodies that can specifically bind to almost any biological or chemical structure imaginable. This remarkable repertoire of antibody specificity is defined by the variable region domains of the heavy (VH) and light (VL) chains of the heterodimeric antigenic determinant region, which generates an estimated 1-6 X 106 combinations in mice and humans through the rearrangement of VH and VL genes.
Antibodies have become an important part of the therapeutic landscape. During the pre-clinical and clinical evaluation stages, detection of the antibody drug is critical to evaluate dose, toxicity, and efficacy. Remember, the antibody drug has been developed to “look” identical, or as much as possible, to natural human antibodies in order to prevent adverse effects in patients.
Using point of care testing and over the counter therapies to lessen the burden of allergic diseases
The prevalence of allergic diseases is increasing worldwide, and every year 400 million people suffer from allergic rhinitis. Allergic diseases are becoming an increasing public health concern and an economic burden. The costs for treating rhinitis in the US have doubled in 5 years to 11 billion US$.
Immunoassays are one of the most widely used technology platforms in the detection of small chemical compounds, proteins, and microorganisms.
In a study published in 2017, several key stakeholders were interviewed to understand their views on what advantages can be gained from point of care (POC) diagnostics in rural primary healthcare (RHC) clinics and to identify some areas for further improvements.